Abstract: Provided are methods for aiding in diagnosis and treatment of non-small cell lung cancer (NSCLC) adenocarcinoma. The methods involve determining elevated circulating Interleukin-18 (IL-18) values to aid in the diagnosis and treatment of NSCLC. Medical interventions based on determining circulating IL-18 levels are provided and include additional scanning, surgical resection of tumors, and administration of adjuvant therapy, such as chemotherapy or immune therapy.

Abstract: In accordance with certain exemplary embodiments of the present disclosure, exemplary visualization system, method, procedure and computer-accessible medium can be provided, which individually and/or collectively can be called, e.g., ImmunoRuler (IR). Certain exemplary embodiments of the exemplary IR in accordance with the present disclosure can be used for, e.g., comparing two groups of objects with specific and distinguished properties, such as a group of case subjects with a particular disease and a group of control subjects without that particular disease, and/or a group of subjects with a particular disease who are given a treatment and a group of subjects with the same disease but under another treatment or no treatment at all.

Abstract: Several embodiments provided herein relate to methods of diagnosing asbestos exposure or mesothelioma. Several embodiments also relate to methods of differentiating whether a tumor of the lung is lung cancer or mesothelioma.

Abstract: The present invention relates to a therapeutic comprising an osteopontin isoform a (“OPNa”) inhibitor where the OPNa inhibitor blocks activity of extracellular OPNa exon 4. The OPNa inhibitor is selected from the group consisting of (i) an exon-4 specific antibody or binding portion thereof; (ii) a peptide mimic of OPNa exon 4 or a fragment thereof; (iii) a nucleic acid aptamer that specifically binds to OPNa exon 4 or a fragment thereof; and (iv) a peptide inhibitor that binds to OPNa exon 4 or a fragment thereof. The present invention also relates to methods of inhibiting tumor growth and/or metastasis in a subject, treating a subject with chemotherapeutic resistance, and methods of increasing tumor cell sensitivity to a cancer therapeutic by administering an OPNa inhibitor according to the present invention.

Abstract: The method of the present disclosure is directed towards a method and a kit for diagnosing a cell proliferative disease. This method includes the following steps; gathering a sample from a subject, measuring the fibulin expression level or measuring the fibulin activity level in the sample, comparing the measured fibulin expression level or measured fibulin activity level to a baseline level of fibulin expression or activity and assigning the subject to a normal or abnormal group based on the measured fibulin expression level or activity level in the sample. The present disclosure is also directed towards a kit for diagnosing a cell proliferative disease. The kit includes a sampler, a measurer, a comparor and an assignor.

Abstract: Several embodiments provided herein relate to methods of diagnosing asbestos exposure or mesothelioma. Several embodiments also relate to methods of differentiating whether a tumor of the lung is lung cancer or mesothelioma.

Abstract: In accordance with certain exemplary embodiments of the present disclosure, exemplary visualization system, method, procedure and computer-accessible medium can be provided, which individually and/or collectively can be called, e.g., ImmunoRuler (IR). Certain exemplary embodiments of the exemplary IR in accordance with the present disclosure can be used for, e.g., comparing two groups of objects with specific and distinguished properties, such as a group of case subjects with a particular disease and a group of control subjects without that particular disease, and/or a group of subjects with a particular disease who are given a treatment and a group of subjects with the same disease but under another treatment or no treatment at all.

Abstract: The present invention provides diagnostic methods based on levels of osteopontin.

Abstract: The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample.

Abstract: The present invention provides prognostic and diagnostic methods related to pleural mesotheliomas based on levels of osteopontin in bodily fluids.

Abstract: The present invention provides diagnostic methods based on the levels of osteopontin.

Abstract: The present invention provides diagnostic methods based on the serum levels of osteopontin.

Abstract: A device for applying light in photodynamic therapy is arranged to apply light in a pattern corresponding to the configuration of the lesion to be treated. The device may be customized in response to an image of the patient acquired before treatment. Alternatively, the device may include sensors for detecting a characteristic of tissue overlying each region of the device so that the device either emits light or does not emit light in each region depending upon the characteristics of the overlying tissue.

Abstract: A light sensor constructed from a commercial photodiode packaged in a transparent housing of sufficient thickness to set the photodetector away from the underlying surface, thereby reducing the shadowing effects of the photodetector and allowing incident light to pass through the housing to the tissue below. Electrical connections are made directly on the photodiode which is sealed within the transparent housing, thus avoiding electrical shock or short circuit hazards. The transparent package is equipped with four hooks which are well suited for attachment to tissue structure, either directly or with the aid of sutures. In a second embodiment, the light sensor includes a second photodiode mounted within the sealed housing to measure light reflected from the underlying tissue. The light sensor is well suited for use with photodynamic therapy.